Managers / Q2 2025 · view latest →
TRIGLAV INVESTMENTS, D.O.O.
CIK 0002056690 · DUNAJSKA CESTA 20, LJUBLJANA, 1000 · 00386 01 3007300
Summary
Triglav Investments, D.o.o. reported $1.4B in U.S.-listed holdings across 131 positions for Q2 2025.
Its largest position, NVDA, represents 9.9% of the portfolio.
Compared with Q1 2025, the fund opened 9 new positions and exited 10.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 94.1% · $1.3B
- ETP · 1.9% · $26M
- ADR · 1.7% · $23M
- Other · 1.5% · $21M
- REIT · 0.6% · $8M
- Other · 0.2% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RLRALPH LAUREN CORPORATION | NEW | +40.5K | 40.5K | +$11M | $11M |
| DASHDOORDASH INC | NEW | +30.5K | 30.5K | +$8M | $8M |
| EQIXEQUINIX, INC. | NEW | +9.0K | 9.0K | +$7M | $7M |
| BKNGBOOKING HOLDINGS INC. | NEW | +950 | 950 | +$5M | $5M |
| MRVLMARVELL TECHNOLOGY INC | NEW | +20.0K | 20.0K | +$2M | $2M |
| REGNREGENERON PHARMACEUTICALS, INC. | NEW | +2.5K | 2.5K | +$1M | $1M |
| UTHUNITED THERAPEUTICS CORP | NEW | +4.0K | 4.0K | +$1M | $1M |
| ROYAL CARIBBEAN CRUISES LTD. | NEW | +0 | 0 | +$0 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $1.4B | 166 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $1.6B | 173 | Feb 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $1.5B | 140 | Nov 5, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $1.4B | 131 | Aug 5, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $1.2B | 139 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $1.3B | 126 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.